DaVita to Present 11 Abstracts at the American Society of Nephrology’s Kidney Week 2011
November 10 2011 - 9:00AM
Business Wire
DaVita Inc. (NYSE: DVA), a leading provider of kidney care
services committed to improving the quality of life for those
diagnosed with chronic kidney disease (CKD), today announced the
presentation of 11 studies at this year’s American Society of
Nephrology’s (ASN) Kidney Week. DaVita® will be at booth 1801
during the November 8-13 meeting in Philadelphia.
ASN’s Kidney Week is the world’s premier nephrology meeting and
serves as a platform for more than 13,000 kidney professionals from
around the globe to exchange knowledge, learn the latest scientific
and medical advances, and listen to leading experts in the
field.
DaVita Chief Medical Officer Allen R. Nissenson, M.D., noted,
“At this year’s ASN meeting study results from innovative clinical
improvement programs and health economic analyses will be presented
by DaVita researchers and its research partners.”
A major focus for abstracts this year is the unique ability of
an integrated care model to drive significant improvements in
patient outcomes. One such abstract, by Rizkalla, et al, is titled
the “Effect of an Integrated Care Delivery System on Improving
Immunization Outcomes.” The study demonstrated dramatic improvement
in annual vaccination rates within a large population of dialysis
patients. This is especially important given the direct correlation
between improved vaccination rates and reduced patient
morbidity.
Similarly, results of an analysis of DaVita’s CathAway™ program
– designed to transition patients from central venous catheters
(CVCs) to arteriovenous fistulas – will be presented by Glowalla,
et al, in the poster “Improvements in Clinical and Operational
Outcomes for a Cohort of Patients Converted from Central Venous
Catheter Access.” This study demonstrates that transitioning
patients off of their CVCs and optimizing patients’ mode of
vascular access improves the patient outcomes and reduces the use
of agents required to keep CVCs patent.
Van Wyck, et al, will present a study titled the “Clinical
Utility of Tests for Hepatitis C Surveillance.” Although KDIGO®,
KDOQI, and CDC recommendations each specify screening seronegative
patients every 6-12 months for the surveillance of HCV infection in
HD facilities, the clinical utility of recommended tests has not
been examined in large populations. They found evidence that
reactivity in HCV screening antibody assays wanes of fluctuates in
HCV-positive patients. The findings suggest that when expected
seroconversion rates are low, HCV surveillance in seronegative
patients should be conducted no more frequently than annually, and
new positive screening results in HD patients should be interpreted
with caution and should undergo case-by-case clinical
adjudication.
DaVita and CathAway are registered trademarks of DaVita Inc. All
other trademarks are the property of their respective owners.
About DaVita
DaVita Inc., a Fortune 500® company, is a leading provider of
kidney care in the United States, delivering dialysis services to
patients with chronic kidney failure and end stage renal disease.
DaVita strives to improve patients’ quality of life by innovating
clinical care, and by offering integrated treatment plans,
personalized care teams and convenient health-management services.
As of September 30, 2011, DaVita operated or provided
administrative services at 1,777 dialysis facilities, serving
approximately 138,000 patients. DaVita supports numerous programs
dedicated to creating positive, sustainable change in communities
around the world. The company’s leadership development initiatives
and social responsibility efforts have been recognized by Fortune,
Modern Healthcare, Newsweek and WorldBlu. For more information,
please visit www.davita.com.
DaVita (NYSE:DVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Sep 2023 to Sep 2024